
Hemostats Patent Landscape Report
Description
Hemostats Patent Landscape Report
Global Hemostats Patent Landscape Report 2024 Global Hemostats Industry Size The global hemostats market was valued at USD 2.9 billion in 2023. The market is expected to grow at a CAGR of 6.4% during the forecast period of 2024-2032, with the values likely to rise from USD 3.1 billion in 2024 to USD 5.1 billion by 2032. The United States is at the forefront of the patent landscape with over 5,500 patents, reflecting the nation's robust innovation in hemostatic technologies. Patent Landscape Report Coverage This report offers a comprehensive understanding of the global hemostats patent landscape. It covers trends in patent filings, significant technological advancements, and emerging innovations in the hemostats sector. The report includes detailed information on patent filings, grants, and the leading companies driving progress in hemostatic technologies. By highlighting strategic developments and advanced technologies, this report is an invaluable resource for stakeholders seeking to understand the intellectual property dynamics and competitive landscape of the hemostats industry. Global Hemostat Patent Outlook • The global hemostats patent landscape is fueled by biocompatible materials and novel formulations, with over 5,000 filed. Advancements aim to enhance hemostatic efficacy, minimise adverse reactions, and promote natural healing processes. The integration of hemostats with minimally invasive and robotic surgical techniques further fuels innovation. • Ethicon Inc., Tepha Inc., and Tyco Healthcare are leading companies in the hemostatic technology industry, filing numerous patents for bio-resorbable materials and surgical solutions. Their focus on patient safety and surgical outcomes is driving significant patent activity, positioning them as key players in the industry's future. • The US leads the patent landscape for hemostats with over 5,500 patents, focusing on advanced materials and regulatory compliance. Europe, particularly Germany and the UK, contributes 3,500 patents, focusing on safety and surgical standards. The Asia-Pacific region, led by China and Japan, is emerging with over 3,000 patents, driven by cost-effective and scalable hemostatic solutions. Hemostat: Introduction Hemostats are critical tools in surgical procedures, designed to achieve hemostasis by promoting the clotting of blood. These devices are used to control bleeding during surgery, facilitating quicker recovery and reducing the risk of complications. The patent landscape for hemostats is driven by the need for more effective hemostatic agents, integration with advanced surgical techniques, and development of bio-compatible materials. • The advancement of biocompatible materials is essential for enhancing the safety and effectiveness of hemostats. Over 5,000 patents focus on the development of these advanced materials, which are designed to enhance hemostatic efficacy and minimise adverse reactions. These materials are crucial in reducing inflammation and promoting natural healing processes post-surgery. • The integration of hemostats with modern surgical technologies is a key focus area. Approximately 4,200 patents emphasize the integration of hemostats with robotic and minimally invasive surgical techniques. This integration enhances precision and effectiveness, ensuring rapid hemostasis in complex surgical environments and improving overall surgical outcomes. • The development of novel hemostatic formulations is critical for improving patient outcomes. Around 3,800 patents focus on these advanced formulations that offer rapid action and a longer duration of effect. These innovations ensure reliable bleeding control during and after surgical procedures, enhancing patient safety and recovery. These drivers contribute to a dynamic patent landscape, fostering innovations that enhance the effectiveness, safety, and integration of hemostats in surgical care. Global Hemostats Patent Segmentation Analysis The report provides an in-depth analysis of the patents in this field by the following segmentation: Analysis by Product Type • Combination • Oxidized Regenerated Cellulose Based • Gelatine Based • Collagen Based Hemostat The patent landscape for hemostats is segmented by product type into combination, oxidized regenerated cellulose-based, gelatine-based, and collagen-based hemostats. Among these, oxidized regenerated cellulose-based hemostats have led with over 3,000 patents filed and 400 new filings recently. This segment's leadership is due to its excellent biocompatibility and effectiveness in controlling bleeding, making it a preferred choice in various surgical procedures. The future scope involves enhancing hemostatic properties and expanding applications across diverse surgical fields. Analysis by Instrument Type • Halstead Mosquito Hemostatic Forceps • Kelly And Crile Hemostatic Forceps • Rochester-Carmalt Hemostatic Forceps The patent landscape for hemostats is segmented by instrument type into Halstead mosquito hemostatic forceps, Kelly and Crile hemostatic forceps, and Rochester-Carmalt hemostatic forceps. Kelly and Crile hemostatic forceps dominate this segment, with over 2,500 patents filed and 300 new applications recently. Their versatility and precision in clamping small blood vessels enhance their utility in diverse surgical contexts, with future advancements focused on improving ergonomics and material durability. Analysis by Formulation • Matrix and Gel Hemostats • Sheet and Pad Hemostats • Sponge Hemostats • Powder Hemostats Based on formulation, the patent landscape includes matrix and gel hemostats, sheet and pad hemostats, sponge hemostats, and powder hemostats. Matrix and gel hemostats lead this segment, with over 2,800 patents filed and 350 new patents recently. These formulations offer rapid action and are easily applied in challenging surgical fields, making them indispensable in modern surgical practice. Future developments aim to improve biodegradability and effectiveness in various clinical settings. Analysis by Application • Orthopaedic • General surgery • Neurological surgery • Cardiovascular surgery • Reconstructive surgery • Gynaecological surgery The patent segmentation based on application includes orthopedic, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, and gynecological surgery. General surgery applications dominate, with over 3,200 patents and 450 new filings recently. These patents focus on enhancing hemostatic efficiency in a wide range of surgical procedures, ensuring rapid and reliable bleeding control. Future scope includes expanding into minimally invasive and robotic surgeries. Analysis by End User • Ambulatory Centers • Hospitals • Clinics • Community Healthcare • Others The patent segmentation based on end user includes ambulatory centres, hospitals, clinics, community healthcare, and others. Hospitals lead the patent landscape, with over 3,600 patents historically and more than 500 new filings recently. This dominance is driven by the development of advanced hemostatic solutions that improve surgical outcomes and patient safety in hospital settings. Future innovations are expected to integrate hemostats with hospital IT systems for enhanced surgical workflows. Hemostats Patent Jurisdiction Analysis The global patent landscape for hemostats exhibits diverse regional focuses and innovations. In North America, particularly the United States, over 5,500 patents emphasize the development of advanced hemostatic materials and surgical techniques. European countries, such as Germany and the UK, hold over 3,500 patents, focusing on regulatory compliance and safety standards. The Asia-Pacific region, led by China and Japan, has filed over 3,000 patents, driven by the demand for cost-effective and efficient hemostatic solutions to support expanding healthcare systems. Patent Profile of Key Companies The patent landscape for hemostats is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities: Ethicon Inc Ethicon Inc., based in Somerville, New Jersey, holds over 1,800 patents related to hemostatic devices, with approximately 200 patents in progress. The company focuses on innovations in biocompatible materials and advanced formulations, enhancing hemostatic efficacy and patient safety. Tepha Inc Headquartered in Lexington, Massachusetts, Tepha Inc. has filed over 1,500 patents in the hemostat sector, with around 150 patents currently in progress. The company specialises in developing bio-resorbable materials that offer effective hemostasis and promote natural healing processes. Tyco Healthcare Tyco Healthcare, located in Mansfield, Massachusetts, holds over 1,600 patents related to hemostats, with approximately 180 patents in progress. The company focuses on innovative hemostatic solutions that integrate seamlessly with modern surgical practices, improving surgical outcomes and efficiency. Other key players in the industry include Omrix Biopharmaceuticals Inc. and Joshua R&d Technologies LLc. Key Questions Answered in the Global Hemostats Patent Landscape Report • What are the key drivers of increasing patent activitiesin hemostatic technology? • How do patent trends vary across different regions in the hemostat landscape? • Which companies are leading in patent filings for hemostats? • What technological advancements are shaping the patent landscape of hemostatic solutions? • How is the demand for biocompatible materials influencing patent activity? • What challenges are faced by patent landscapein the development and implementation of hemostatic devices? • How is regulatory compliance impacting the patent landscape for these devices? • How are patents addressing the integration of hemostats with surgical techniques? • What are the trends in patent filings for product and instrument types? • How is the Asia-Pacific region contributing to the hemostat patent landscape? • What innovations are being developed to enhance surgical outcomes and safety? • How are hospitals and surgical centers driving patent activity in hemostatic technology? Reasons to Purchase this Report This report offers an in-depth analysis of the patent landscape, covering key trends, technological advancements, and regional insights. It provides detailed segmentation and highlights areas of significant innovation and activity. By examining leading companies' strategies and patent portfolios, the report elucidates competitive dynamics and emerging opportunities. Stakeholders will gain valuable information for strategic decision-making, ensuring they stay ahead in the evolving landscape. This comprehensive coverage makes it an essential resource for understanding the industry's future direction.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Hemostats Market Overview
- 3.1 Global Hemostats Market Historical Value (2017-2023)
- 3.2 Global Hemostats Market Forecast Value (2024-2032)
- 4 Global Hemostats Market Landscape
- 4.1 Global Hemostats Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Hemostats Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Instrument Type
- 4.2.3 Analysis by Formulation
- 5 Global Hemostats Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Hemostats Market Segmentation (2017-2032)
- 6.1 Global Hemostats Market (2017-2032) by Product Type
- 6.1.1 Market Overview
- 6.1.2 Combination
- 6.1.3 Oxidized Regenerated Cellulose Based
- 6.1.4 Gelatine Based
- 6.1.5 Collagen Based Haemostat
- 6.2 Global Hemostats Market (2017-2032) by Instrument Type
- 6.2.1 Market Overview
- 6.2.2 Halstead Mosquito Hemostatic Forceps
- 6.2.3 Kelly And Crile Hemostatic Forceps
- 6.2.4 Rochester-Carmalt Hemostatic Forceps
- 6.3 Global Hemostats Market (2017-2032) by Formulation
- 6.3.1 Market Overview
- 6.3.2 Matrix and Gel Hemostats
- 6.3.3 Sheet and Pad Hemostats
- 6.3.4 Sponge Hemostats
- 6.3.5 Powder Hemostats
- 6.4 Global Hemostats Market (2017-2032) by Application
- 6.4.1 Market Overview
- 6.4.2 Orthopaedic
- 6.4.3 General surgery
- 6.4.4 Neurological surgery
- 6.4.5 Cardiovascular surgery
- 6.4.6 Reconstructive surgery
- 6.4.7 Gynaecological surgery
- 6.5 Global Hemostats Market (2017-2032) by Indication
- 6.5.1 Market Overview
- 6.5.2 Closure
- 6.5.3 Surgery
- 6.6 Global Hemostats Market (2017-2032) by End User
- 6.6.1 Market Overview
- 6.6.2 Ambulatory Centers
- 6.6.3 Hospitals
- 6.6.4 Clinics
- 6.6.5 Community Healthcare
- 6.6.6 Others
- 6.7 Global Hemostats Market (2017-2032) by Distribution Channel
- 6.7.1 Market Overview
- 6.7.2 Hospitals
- 6.7.3 Ambulatory Surgical Centers
- 6.7.4 Clinics
- 6.7.5 Online Channels
- 6.8 Global Hemostats Market (2017-2032) by Region
- 6.8.1 Market Overview
- 6.8.2 North America
- 6.8.3 Europe
- 6.8.4 Asia Pacific
- 6.8.5 Latin America
- 6.8.6 Middle East and Africa
- 7 North America Hemostats Market (2017-2032)
- 7.1 North America Hemostats Market (2017-2032) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Combination
- 7.1.3 Oxidized regenerated cellulose based
- 7.1.4 Gelatine based
- 7.1.5 Collagen based haemostat
- 7.2 North America Hemostats Market (2017-2032) by Instrument Type
- 7.2.1 Market Overview
- 7.2.2 Halstead Mosquito Hemostatic Forceps
- 7.2.3 Kelly And Crile Hemostatic Forceps
- 7.2.4 Rochester-Carmalt Hemostatic Forceps
- 7.3 North America Hemostats Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Hemostats Market (2017-2032)
- 8.1 Europe Hemostats Market (2017-2032) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Combination
- 8.1.3 Oxidized regenerated cellulose based
- 8.1.4 Gelatine based
- 8.1.5 Collagen based haemostat
- 8.2 Europe Hemostats Market (2017-2032) by Instrument type
- 8.2.1 Market Overview
- 8.2.2 Halstead Mosquito Hemostatic Forceps
- 8.2.3 Kelly And Crile Hemostatic Forceps
- 8.2.4 Rochester-Carmalt Hemostatic Forceps
- 8.3 Europe Hemostats Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Hemostats Market (2017-2032)
- 9.1 Asia Pacific Hemostats Market (2017-2032) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Combination
- 9.1.3 Oxidized regenerated cellulose based
- 9.1.4 Gelatine based
- 9.1.5 Collagen based haemostat
- 9.2 Asia Pacific Hemostats Market (2017-2032) by Instrument type
- 9.2.1 Market Overview
- 9.2.2 Halstead Mosquito Hemostatic Forceps
- 9.2.3 Kelly And Crile Hemostatic Forceps
- 9.2.4 Rochester-Carmalt Hemostatic Forceps
- 9.3 Asia Pacific Hemostats Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Others
- 10 Latin America Hemostats Market (2017-2032)
- 10.1 Latin America Hemostats Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Combination
- 10.1.3 Oxidized regenerated cellulose based
- 10.1.4 Gelatine based
- 10.1.5 Collagen based haemostat
- 10.2 Latin America Hemostats Market (2017-2032) by Instrument Type
- 10.2.1 Market Overview
- 10.2.2 Halstead Mosquito Hemostatic Forceps
- 10.2.3 Kelly And Crile Hemostatic Forceps
- 10.2.4 Rochester-Carmalt Hemostatic Forceps
- 10.3 Latin America Hemostats Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Hemostats Market (2017-2032)
- 11.1 Middle East and Africa Hemostats Market (2017-2032) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Combination
- 11.1.3 Oxidized regenerated cellulose based
- 11.1.4 Gelatine based
- 11.1.5 Collagen based haemostat
- 11.2 Middle East and Africa Hemostats Market (2017-2032) by Instrument Type
- 11.2.1 Market Overview
- 11.2.2 Halstead Mosquito Hemostatic Forceps
- 11.2.3 Kelly And Crile Hemostatic Forceps
- 11.2.4 Rochester-Carmalt Hemostatic Forceps
- 11.3 Middle East and Africa Hemostats Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Pfizer Inc.
- 17.1.1 Company Overview
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Stryker
- 17.2.1 Company Overview
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Integra LifeSciences
- 17.3.1 Company Overview
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Hemostasis, LLC
- 17.4.1 Company Overview
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Teleflex Incorporated
- 17.5.1 Company Overview
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Medtronic
- 17.6.1 Company Overview
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 B. Braun SE
- 17.7.1 Company Overview
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Johnson & Johnson Services, Inc.
- 17.8.1 Company Overview
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 BD
- 17.9.1 Company Overview
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Baxter
- 17.10.1 Company Overview
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Marine Polymer Technologies, Inc.
- 17.11.1 Company Overview
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Teleflex Incorporated
- 17.12.1 Company Overview
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Gelita Medical
- 17.13.1 Company Overview
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Anika Therapeutics, Inc.
- 17.14.1 Company Overview
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Mil Laboratories Pvt. Ltd.
- 17.15.1 Company Overview
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 18 Global Hemostats Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.